Cite
HARVARD Citation
Kim, H. et al. (2020). Cost‐effectiveness and financial risks associated with immune checkpoint inhibitor therapy. British journal of clinical pharmacology. 86 (9), pp. 1703-1710. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Kim, H. et al. (2020). Cost‐effectiveness and financial risks associated with immune checkpoint inhibitor therapy. British journal of clinical pharmacology. 86 (9), pp. 1703-1710. [Online].